Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 15/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640928 | 0.93 | MAPT (0.43) | MAPTMEN1KMT2AF10CNR1 | |
| SCHEMBL5643192 | 0.90 | CNR1 (0.54) | MAPTMEN1KMT2ACNR1PAK1 | |
| SCHEMBL5640620 | 0.85 | F10 (0.58) | MAPTMEN1KMT2AF10LMNA | |
| SCHEMBL5643218 | 0.84 | F10 (0.44) | MAPTMEN1KMT2AF10CNR1 | |
| SCHEMBL5638208 | 0.83 | F10 (0.58) | MAPTMEN1KMT2AF10LMNA | |
| SCHEMBL5639265 | 0.83 | F10 (0.44) | MAPTMEN1KMT2AF10 | |
| SCHEMBL5639021 | 0.81 | F10 (0.58) | F10 | |
| SCHEMBL4594684 | 0.81 | F10 (0.55) | F10LMNATP53 | |
| SCHEMBL5641757 | 0.80 | F10 (0.55) | F10 | |
| SCHEMBL5640312 | 0.80 | CNR1 (0.38) | MAPTMEN1KMT2AF10CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | MAPT 4614/4885MEN1 671/4885KMT2A 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.